Jeff Martin
Stock Analyst at Roth MKM
(4.45)
# 260
Out of 4,784 analysts
63
Total ratings
60%
Success rate
16.56%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $3.70 | +143.24% | 1 | Mar 20, 2025 | |
| NVEE NV5 Global | Maintains: Buy | $27 → $28 | $19.25 | +45.45% | 7 | Feb 21, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $178 → $224 | $193.32 | +15.87% | 15 | Jan 24, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $41.21 | +9.20% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $29.17 | +2.85% | 6 | Nov 5, 2024 | |
| BWMN Bowman Consulting Group | Maintains: Buy | $47 → $43 | $22.68 | +89.59% | 5 | Aug 8, 2024 | |
| FC Franklin Covey Co. | Reiterates: Buy | $50 | $28.03 | +78.38% | 7 | Jun 27, 2024 | |
| PERI Perion Network | Downgrades: Neutral | $35 → $13 | $8.16 | +59.31% | 7 | Apr 9, 2024 | |
| NSP Insperity | Maintains: Buy | $144 → $147 | $88.08 | +66.89% | 8 | Apr 27, 2023 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $1.59 | +362,164.15% | 2 | Nov 15, 2017 |
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.70
Upside: +143.24%
NV5 Global
Feb 21, 2025
Maintains: Buy
Price Target: $27 → $28
Current: $19.25
Upside: +45.45%
OSI Systems
Jan 24, 2025
Maintains: Buy
Price Target: $178 → $224
Current: $193.32
Upside: +15.87%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $41.21
Upside: +9.20%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $29.17
Upside: +2.85%
Bowman Consulting Group
Aug 8, 2024
Maintains: Buy
Price Target: $47 → $43
Current: $22.68
Upside: +89.59%
Franklin Covey Co.
Jun 27, 2024
Reiterates: Buy
Price Target: $50
Current: $28.03
Upside: +78.38%
Perion Network
Apr 9, 2024
Downgrades: Neutral
Price Target: $35 → $13
Current: $8.16
Upside: +59.31%
Insperity
Apr 27, 2023
Maintains: Buy
Price Target: $144 → $147
Current: $88.08
Upside: +66.89%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $1.59
Upside: +362,164.15%